A University of California, Berkeley study published in Nature found that 20-month-old mice treated with semaglutide lived an average of 834 days compared to 742 days for placebo-treated mice.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

The FAHR-FaceAge tool estimates a patient's biological age from a photo, while FAHR-FaceSurvival predicts cancer survival outcomes directly from a facial photograph.

FAHR-FaceSurvival directly learns cancer mortality risk from facial photographs without inferring survival through an intermediate biological age calculation.

Mass General Brigham researchers expanded their work through an online, institutional review board-approved public study where participants upload facial photographs to receive biological age readouts.

More young people need to get their brain scanned

In the Sungkyunkwan University cohort, each 1-unit increase in biological age acceleration based on nine routine blood markers was associated with a 7% higher risk of early-onset colorectal adenocarcinoma.

Accelerated biological aging was associated with higher risk for colon adenocarcinoma, while showing no statistically significant association with rectal adenocarcinoma or neuroendocrine tumors.

A Sungkyunkwan University study of 198,491 Korean adults under 50 published in Clinical Gastroenterology and Hepatology linked accelerated biological aging to a 93% higher risk for early-onset colorectal adenocarcinoma.

Old age can be the happiest time of life

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition